Article
Hematology
Jin Mao, Hua Yin, Li Wang, Jia-Zhu Wu, Yi Xia, Hua-Yuan Zhu, Lei Fan, Jian-Yong Li, Jin-Hua Liang, Wei Xu
Summary: Vitamin D deficiency is an independent prognostic factor for inferior survival outcomes in ENKTL patients, and adding 25-(OH)D deficiency to the PINK-E score system improves the prognostic significance for progression-free survival and overall survival.
ANNALS OF HEMATOLOGY
(2021)
Article
Oncology
Tao Hai, Wanchun Wu, Kexin Ren, Na Li, Liqun Zou
Summary: This study found that the systemic immune-inflammation index (SII) can serve as a prognostic marker for extranodal natural killer/T-cell lymphoma (ENKTCL), predicting poorer survival in low-risk patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Na Li, Ming Jiang, Wan-Chun Wu, Li-Qun Zou
Summary: This study aimed to evaluate the impact of prognostic nutritional index (PNI) in extranodal natural killer/T-cell lymphoma (ENKTL) and provide additional prognostic information for risk stratification and clinical decision-making. The study found that PNI and PNI-associated prognostic score could be independent prognostic factors for ENKTL and may be useful for risk stratification.
ANNALS OF HEMATOLOGY
(2022)
Article
Nutrition & Dietetics
Tiange Lu, Xue Shi, Xueling Ge, Ying Li, Yiqing Cai, Xiaomin Chen, Shunfeng Hu, Mei Ding, Xiaosheng Fang, Fang Liu, Xiangxiang Zhou, Xin Wang
Summary: In this study, the significance of nutritional status in extranodal NK/T-cell lymphoma (ENKTL) was explored, and a new scoring system (CONUT-PINK-E) was developed to assess patients' nutritional status and prognosis. The results showed that CONUT-PINK-E could independently predict patients' overall survival and progression-free survival, and presented superior discrimination and clinical benefit compared to current models.
FRONTIERS IN NUTRITION
(2023)
Review
Oncology
Ajay Major, Pierluigi Porcu, Bradley M. Haverkos
Summary: This review summarizes the research on the biological causes of ENKTL and the identification of new therapeutic targets and biomarkers, which may enable a personalized medicine approach towards ENKTL therapy.
Article
Oncology
Xindi Liu, Yuanzheng Liang, Ziyuan Shen, Liqiang Wei, Jing Yang, Yingshi Piao, Wei Sang, Pengfei Li, Liang Wang
Summary: The study aimed to evaluate the role of nomogram-revised risk index (NRI) in patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTCL) and establish a new prognostic model. It was found that serum ferritin level could be a novel prognostic factor in ENKTCL patients, and integrating NRI with clinical parameters can better predict the prognosis of ENKTCL.
Article
Biochemistry & Molecular Biology
Rong Tao, Lei Fan, Yongping Song, Yu Hu, Wei Zhang, Yafei Wang, Wei Xu, Jianyong Li
Summary: The study demonstrated that sintilimab is effective and well tolerated in patients with relapsed/refractory extranodal NK/T cell lymphoma, with a low rate of adverse events. It could be a novel therapeutic approach for controlling this type of cancer.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Biology
Hyunsung Kim, Young Hyeh Ko
Summary: Extranodal NK/T-cell lymphoma is a tumor that occurs in extranodal sites, most commonly in the nasal cavity. It is associated with the presence of the EBV genome, specific immunophenotypes, and mutations in certain pathways and genes. Understanding the molecular pathogenesis of ENKTL and developing better treatment strategies are important for managing this disease.
Article
Medicine, Research & Experimental
Liang Wang, Jing Yang, He-nan Wang, Rui-ying Fu, Xin-di Liu, Ying-shi Piao, Li-qiang Wei, Jing-wen Wang, Luo Zhang
Summary: The study found that BCYRN1 is overexpressed in ENKTCL compared to normal NK cells, and its high expression is significantly correlated with poorer progression-free survival in patients. BCYRN1 promotes resistance to ASP by inducing autophagy, which can be reversed by inhibition of autophagy.
Review
Immunology
Zheng Yan, Shuna Yao, Zhizhong Wang, Wenping Zhou, Zhihua Yao, Yanyan Liu
Summary: Extranodal NK/T-cell lymphoma (ENKTCL) is a common subtype of T/NK-cell lymphoma in Asia and Latin America, but rare in North America and Europe. The survival rate has significantly improved over the past two decades, attributed to advances in radiation technology and the introduction of asparaginase and immunotherapy. Treatment is trending towards simpler regimens, less toxicity, and higher efficacy, with investigations into novel drugs ongoing. It is recommended to focus on optimizing the use of asparaginase and immunotherapy, overcoming resistance, and identifying novel treatment targets.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Boheng Li, Qidi Zhou, Qin Wan, Xuan Qiao, Shangying Chen, Jianbiao Zhou, Zhijun Wuxiao, Lei Luo, Siok-Bian Ng, Jieping Li, Wee-Joo Chng
Summary: This study identifies TRIP12 as an E3 ligase that triggers polyubiquitination of EZH2, leading to its stabilization and promoting ENKTL cell migration. The TRIP12-EZH2 axis can be regulated by cytoplasmic HSP60 and targeted by dexamethasone treatment.
CLINICAL EPIGENETICS
(2023)
Article
Oncology
Jiwei Li, Jin Li, Meizuo Zhong, Hui Zhou, Baohua Yu
Summary: Advanced stage extranodal natural killer/T-cell lymphoma (ENKTL) is a distinct type of non-Hodgkin lymphoma with poor prognosis. This study investigated clinical features, treatment strategies, and survival outcomes in 107 patients with advanced stage ENKTL. L-asparaginase-containing chemotherapy showed significantly higher 3-year progression-free survival and overall survival rates compared to CHOP, but also had more frequent grade 3/4 toxicities.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Akhil Rajendra, Manju Sengar, V. N. Avinash Bonda, Hasmukh Jain, Lingaraj Nayak, Jayashree Thorat, Tanuja Shet, Sridhar Epari, Siddharth Laskar, Archi Aggarwal, V. Rangarajan, Sumeet Gujral, Bhausaheb Bagal, Sangeeta Kakoti, Omkar Salvi
Summary: The staging, prognostication, and treatment of ENKTL have evolved with better understanding of disease biology. There is significant heterogeneity in the treatment used worldwide. This study investigated the outcomes and prognostic factors of ENKTL patients treated at a center in India between 2010 and 2021. The results showed that L-asparaginase based chemotherapy was administered to 84% of patients, and the median relapse-free survival and overall survival were 45 months for the overall population. PINK score, receipt of radiotherapy, and achievement of complete response were identified as prognostic factors for survival.
LEUKEMIA & LYMPHOMA
(2023)
Article
Oncology
Yu-Ting Zhao, Si-Ye Chen, Xin Liu, Yong Yang, Bo Chen, Yong-Wen Song, Hui Fang, Jing Jin, Yue-Ping Liu, Hao Jing, Yuan Tang, Ning Li, Ning-Ning Lu, Shu-Lian Wang, Han Ouyang, Chen Hu, Jin Liu, Zhi Wang, Fan Chen, Lin Yin, Qiu-Zi Zhong, Kuo Men, Jian-Rong Dai, Shu-Nan Qi, Ye-Xiong Li
Summary: This study aimed to assess the value of multi-modal MRI-based radiomics for predicting overall survival in patients with ENKTCL. Two distinct types of MRI radiomics signatures were identified, and the NRI-M model showed better performance in prognostication compared to traditional risk indices.
Article
Oncology
Akhil Rajendra, Manju Sengar, V. N. Avinash Bonda, Hasmukh Jain, Lingaraj Nayak, Jayashree Thorat, Tanuja Shet, Sridhar Epari, Siddharth Laskar, Archi Aggarwal, V. Rangarajan, Sumeet Gujral, Bhausaheb Bagal, Sangeeta Kakoti, Omkar Salvi
Summary: The staging, prognostication, and treatment of ENKTL have improved over the years with a better understanding of the disease biology. There is significant heterogeneity in the treatment strategies used worldwide. In this study, we examined the outcomes and prognostic factors of ENKTL patients treated at our center between May 2010 and December 2021. L-asparaginase based chemotherapy was administered to 84% of the patients.
LEUKEMIA & LYMPHOMA
(2023)